石藥集團(1093.HK)漲超3%創逾9個月新高 績後獲多家大行上調目標價
格隆匯8月28日丨自26日午間公佈業績後,石藥集團(1093.HK)近日持續上漲,今日盤中一度漲3.41%報17.58港元,創2019年11月以來新高,暫成交4.59億港元,最新總市值1310億港元。該股最近三日已累漲超10%。公司上半年收入125.90億元,同比增12.6%;毛利94.37元,同比增20.8%;股東應占溢利23.14億元,同比增23.2%;擬10送6派0.6港元。業績公佈後,石藥集團獲富瑞上調目標價至22港元,獲高盛上調目標價至20港元。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.